Robert Califf Confirmed to Lead FDA

A narrow Senate vote ends a 13-month period during which the agency has lacked a permanent commissioner.

Written byShawna Williams
| 1 min read
US Capitol with Senate building in the foreground
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

After a contentious confirmation process, the US Senate today voted 50-46 to confirm President Joe Biden’s nominee, cardiologist Robert Califf, to helm the Food and Drug Administration. Califf, who previously led the agency during the final 10 months of President Barack Obama’s administration, drew opposition from some Senate Democrats and from Sen. Bernie Sanders (I-VT) due to his ties to the pharmaceutical industry; he previously worked at Verily, a biotechnology company with the same parent company as Google, and has consulted for several drug companies.

In a statement following the confirmation vote, Sen. Edward Markey (D-MA), who voted no, cites what he calls “the FDA’s egregious mishandling of opioid approvals and its role in enabling the current opioid epidemic.” Markey continues: “I have not received any real commitment from Dr. Califf to truly reform the FDA or to learn from the failures that fueled this public health crisis.”

In comments ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Shawna was an editor at The Scientist from 2017 through 2022. She holds a bachelor’s degree in biochemistry from Colorado College and a graduate certificate in science communication from the University of California, Santa Cruz. Previously, she worked as a freelance editor and writer, and in the communications offices of several academic research institutions. As news director, Shawna assigned and edited news, opinion, and in-depth feature articles for the website on all aspects of the life sciences. She is based in central Washington State, and is a member of the Northwest Science Writers Association and the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies